Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study
about
Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trialHypertriglyceridemia and Cardiovascular Diseases: RevisitedMacrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on AtherosclerosisVorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial.Increased Benefit With Vorapaxar Use in Patients With a History of Myocardial Infarction and Diabetes Mellitus: What the Data Show Us.Differential metabolic actions of specific statins: clinical and therapeutic considerationsHigh-density lipoprotein subclass measurements improve mortality risk prediction, discrimination and reclassification in a cardiac catheterization cohort.Statin Dose and the Risk of Intracerebral Hemorrhage: A Population-Based Longitudinal Study in Taiwan.Dyslipidemia and diabetes: reciprocal impact of impaired lipid metabolism and Beta-cell dysfunction on micro- and macrovascular complications.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyMolecular sources of residual cardiovascular risk, clinical signals, and innovative solutions: relationship with subclinical disease, undertreatment, and poor adherence: implications of new evidence upon optimizing cardiovascular patient outcomes.Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetesStatin escape phenomenon: Fact or fiction?Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery diseaseEvidence-based goals in LDL-C reduction.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Reducing residual risk: modern pharmacochemistry meets old-fashioned lifestyle and adherence improvement.HDL cholesterol and cardiovascular outcomes: what is the evidence?Biomarkers and sustainable innovation in cardiovascular drug development: lessons from near and far afield.Platelet activation as a novel mechanism of atherothrombotic risk in chronic obstructive pulmonary disease.The diagnostic and prognostic potential of plasma extracellular vesicles for cardiovascular disease.Bridging the gap for lipid lowering therapy: plaque regression, coronary computed tomographic angiography, and imaging-guided personalized medicine.Erythrocyte-bound apolipoprotein B in atherosclerosis and mortality.Lipoprotein(a): A Lipoprotein Whose Time Has Come.Introducing the cardiovascular, metabolic and lipoprotein translation section of Journal of Translational Medicine.Façons d’identifier et de prendre en charge la dyslipidémie athérogène: Une conséquence métabolique de l’obésité et du diabète.Impact of Lipoprotein (a) on Long-Term Outcomes in Patients with Coronary Artery Disease Treated with Statin After a First Percutaneous Coronary Intervention.Effect of eicosapentaenoic acid/docosahexaenoic acid on coronary high-intensity plaques detected with non-contrast T1-weighted imaging (the AQUAMARINE EPA/DHA study): study protocol for a randomized controlled trial.Clinical Predictors for Lack of Favorable Vascular Response to Statin Therapy in Patients With Coronary Artery Disease: A Serial Optical Coherence Tomography Study.Comparison of effects of anagliptin and alogliptin on serum lipid profile in type 2 diabetes mellitus patients.Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta-Analysis of 35 Randomized Controlled Trials.Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study.Risk prediction with triglycerides in patients with stable coronary disease on statin treatment.Beyond conventional secondary prevention in coronary artery disease-what to choose in the era of CANTOS, COMPASS, FOURIER, ODYSSEY and PEGASUS-TIMI 54? A review on contemporary literatureGlobal, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
P2860
Q21089697-D7AA5C73-A440-4346-A135-83D039FC1E4FQ26750954-A6DC0E8F-A581-4B54-9B76-C02FABC8B6D1Q26780531-F31C8FF2-AD28-4668-8A76-2944E9D35754Q35195203-8EF8FF19-CBAD-4622-B088-8BBB8C9C4D8AQ36094523-4266BC99-23A6-45E7-83B2-9B2C62F18909Q36406951-AF5930EA-0EA9-4ECF-86B8-44DC204ECEC8Q36609592-35022FE4-E5A2-4F49-AFE1-3238BFFD0966Q36721658-C398F24E-D2A9-42D3-A778-574DA7558798Q36978025-4B167C67-03EA-4300-92B6-0FD38C3C08C6Q37115301-F726351D-282B-477D-81CB-FEF2FBA4A364Q37254899-0B8432E2-0AE5-43D1-B567-DC645BFF054AQ37308578-5E063487-AC32-4814-B818-2D8A61CAECD1Q37652073-F0FEC825-0E5D-4709-B139-E540ED8D3FA8Q37708645-753B38EA-7038-4BA9-B913-D177F0249760Q37714588-2E392BCF-3F1D-4AD9-A6EB-AB36629B4AE6Q38039980-CD5189C7-B3FB-40C2-B694-AB4677121B45Q38079763-80540E3B-9672-4842-B395-456F2BFBF6EAQ38082718-AD8EA54E-30BE-4A43-81DD-8C8B9A080074Q38091371-54B9BC50-29C6-4130-8F22-A078A8F3C704Q38132823-2731581E-395C-4CBD-851A-A4D699EE167AQ38624868-868B2A7D-2A89-46A6-A7D0-EE883D966848Q38665677-75DEC139-FB3B-4757-82CE-8B5D29FC2F85Q38987688-B1686B56-29B2-4C78-97E8-79205A63EB67Q39308941-D474D694-0F58-4FFA-B360-BDC2E9CFAC95Q42463127-1A4944AD-5000-420A-BE3C-8BF031A5F826Q46488015-A0A5F36F-A2E9-46D9-90C2-F78222A4DE84Q47144487-31B2D170-A4CF-47EF-95E4-9C45A6AD6A53Q47178300-8DE9ACF9-B90A-4172-BD6A-51D2CF085D2CQ47230624-EB8D19F9-AD9B-4388-952F-BCEF6610C257Q48156669-E92CFABB-170B-47EF-B36B-AA92EC8E8CB8Q49972440-332CD010-189A-4236-AF7A-112EB4AD524FQ50082747-F3A53999-1FCE-451D-AF51-9B92B1A0EF50Q51319217-86E34CB8-BD94-4D83-8043-1701027DBBE8Q58566675-4E911187-D490-4A03-9648-CC9C327C1F8AQ59131985-0108667B-69AE-4C8F-9A65-5205CF2B49E2
P2860
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Determinants of residual risk ...... ing to New Targets (TNT) study
@ast
Determinants of residual risk ...... ing to New Targets (TNT) study
@en
type
label
Determinants of residual risk ...... ing to New Targets (TNT) study
@ast
Determinants of residual risk ...... ing to New Targets (TNT) study
@en
prefLabel
Determinants of residual risk ...... ing to New Targets (TNT) study
@ast
Determinants of residual risk ...... ing to New Targets (TNT) study
@en
P2093
P2860
P1433
P1476
Determinants of residual risk ...... ing to New Targets (TNT) study
@en
P2093
Andrei Breazna
Benoit J Arsenault
David A Demicco
David D Waters
John J P Kastelein
Nanette K Wenger
Prakash Deedwania
S Matthijs Boekholdt
Samia Mora
P2860
P304
P356
10.1161/CIRCULATIONAHA.111.088591
P407
P577
2012-03-29T00:00:00Z